key: cord-0707750-pccb0tb6
authors: Borman, Andrew M.; Fountain, Holly; Guy, Rebecca; Casale, Ella; Gerver, Sarah M; Elgohari, Suzanne; Brown, Colin S; Hopkins, Susan; Chalker, Victoria J; Johnson, Elizabeth M.
title: Increased mortality in COVID-19 patients with fungal co- and secondary infections admitted to intensive care or high dependency units in NHS hospitals in England
date: 2022-01-04
journal: J Infect
DOI: 10.1016/j.jinf.2021.12.047
sha: 6ca0f6dabe6141a15da9dcfeea3616d197e22a47
doc_id: 707750
cord_uid: pccb0tb6

nan

 Patients with severe COVID-19 disease are at risk of fungal co/secondary infections  COVID-associated pulmonary aspergillosis and candidemia are most common  We estimate impact of fungal infections on outcome in COVID ICU patients in England  Aspergillosis and candidemia independently increase COVID-19-associated mortality  Length-of-stay was extended in COVID-19 patients with either fungal infection Dear Editor,

We read with interest the recent systematic review and meta-analysis by Lansbury et al. which aimed to evaluate the burden of bacterial and fungal co-infections in patients with COVID-19, highlighting the challenges in diagnosing certain fungal infections in this setting and the need for a high level of suspicion of fungal infections in critically-ill COVID-19 patients. 1 Severe COVID-19 disease does predispose patients to fungal co-and particularly secondary infections, with reports describing COVID-associated pulmonary aspergillosis (CAPA) and invasive yeast infections (particularly candidaemia) predominating. [2] [3] [4] [5] [6] [7] [8] [9] [10] Additionally, a devastating wave of COVID-associated mucoromycosis (CAM) impacted the Indian subcontinent in late spring, with tens of thousands of cases reported in India alone. 11 Anecdotal reports and individual case series suggested that each of these fungal complications of COVID-19 increases the risk of poor outcomes, including increased hospital lengths of stay (LoS) and excess mortality. 4, 7, 8, 10 A recent French multi-centre study confirmed significant increased mortality in patients with possible or probable CAPA. 12 Here we report data to quantify the impact of fungal co-and secondary infections on outcomes of Candida data was first linked to the NICCEC data to determine which of the candidemia patients also had a COVID-19 diagnosis. Patients with diagnoses of candidemia that were more than 10 days before or 60 days after a COVID-19 diagnosis were excluded, except where the patients had remained hospitalised for the entire period between diagnoses. Retained records were then linked to the ICU dataset of COVID-19

admissions. Data linkage across the datasets was performed in 3 stages to capture patients with missing key with patients then staying in ICU for a median of 10 days (IQR 2-27) from the fungal diagnosis to discharge.

For CAPA, accurate evaluation of incidence is confounded by multiple factors, including lower likelihood of bronchoalveolar testing of severely ill COVID-19 patients in ICU settings (due to risk of transmission from aerosols), geographic differences in biomarker testing and reporting (which influence incidence estimates), lack of a universally employed diagnostic algorithm and the fact that recovery of an Aspergillus spp. isolate from a COVID-19 respiratory sample is not proof of invasive disease. 2,3,8 Given these constraints, a different approach to estimating excess mortality was employed. Initial data linkage and exclusion was performed against the NICCEC and SUS+ ICU data as above, starting with all UK patients from whom an isolate of Aspergillus fumigatus had been referred to the MRL from any respiratory secretion 9 The crude CFR for COVID-19 cases admitted to ICU with an Aspergillus fumigatus sample was 54.6% (95% CI 42.2-69.9; 65/119 patients). Adjusted for age and sex, this reduced to 44.4% (95% CI 25.6-66.9), higher than the COVID-19 ICU patients with no fungal infection (25.5%; p=0.073). Looking to mortality by CAPA classification, crude CFRs were 67.9% (95% CI 40.8-100.0; 19/28) for possible/probable CAPA and 50.5% (95% CI 37.0-67.4; 46/91) for unlikely or unknown CAPA combined. Numbers were too small to look at age and sex adjusted CFRs by these categories. Finally, median LoS was significantly longer in possible/probable CAPA patients (29.5 days, IQR 23.5-43.5, n=28) than in matched COVID-19 patients in ICU (median LoS 7 days; IQR 3-16; n=34,057; p<0.001). Median time from ICU admission to the Aspergillus sample was similar between possible/probable CAPA patients (16.5 days, IQR 11.5-26.5) and unknown/unlikely CAPA patients (17 days, . This was also the case for time to discharge after the fungal sample, with the median time being 6.5 days (IQR 1.5-20) and 6 days (IQR -1-21) respectively. This analysis has limitations. Cases of candidemia and CAPA are likely to be significantly underestimated as they relied upon laboratories reporting and/or referring isolates to the MRL. Laboratories may have undertaken in-house biomarker testing to aid in the diagnosis of CAPA, which would have helped to better stratify the patients in the "unknown CAPA" cohort. Linkage to SUS+ ICU data could only be done by NHS number and date of birth, so any COVID-19 patients missing these data could not be included.

Nonetheless, these estimations for excess mortality caused by the two most common fungal co-/secondary infections encountered with severe COVID-19 align with prior smaller reports from individual centres (nationwide and worldwide) and the recent French study on CAPA in that mortality and LoS are increased in patients with COVID-19 and fungal co-/secondary infection. 4, 7, 10, 12 This data analysis further emphasises the importance of raised awareness, testing, rapid diagnosis, surveillance and prompt and appropriate treatment of fungal infections in severely ill patients with COVID-19.

The authors have no competing interests to declare.

No specific funding support was received for this study. 

Co-infections in people with COVID-19: a systematic review and meta-analysis

COVID-19 associated pulmonary aspergillosis (CAPA)-From immunology to treatment

Diagnosing COVID-19-associated pulmonary aspergillosis

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory

Confronting and mitigating the risk of COVID-19

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study

COVID-19-Associated Pulmonary Aspergillosis

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

Is the Frequency of Candidemia Increasing in COVID-19

Patients Receiving Corticosteroids? J Fungi (Basel)

Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?

Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study